Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for Vera Therapeutics in a research report issued to clients and investors on Monday, May 5th. HC Wainwright analyst A. He anticipates that the company will post earnings per share of ($0.81) for the quarter. HC Wainwright currently has a "Buy" rating and a $75.00 target price on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics' Q3 2025 earnings at ($0.79) EPS and Q4 2025 earnings at ($0.77) EPS.
Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period last year, the firm posted ($0.56) EPS.
Several other research firms have also recently weighed in on VERA. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target on the stock. Wedbush dropped their target price on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Guggenheim boosted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. JPMorgan Chase & Co. dropped their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 4th. Finally, Cantor Fitzgerald dropped their target price on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Vera Therapeutics presently has an average rating of "Buy" and a consensus target price of $63.33.
Read Our Latest Research Report on VERA
Vera Therapeutics Stock Up 4.9%
Vera Therapeutics stock traded up $1.06 during midday trading on Wednesday, hitting $22.77. 204,200 shares of the stock were exchanged, compared to its average volume of 990,105. Vera Therapeutics has a 52-week low of $18.53 and a 52-week high of $51.61. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -8.72 and a beta of 1.28. The business's 50-day moving average price is $24.22 and its 200-day moving average price is $34.65. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.
Institutional Trading of Vera Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. Huntington National Bank bought a new stake in Vera Therapeutics during the 4th quarter worth approximately $26,000. AlphaQuest LLC bought a new stake in Vera Therapeutics during the 4th quarter worth approximately $34,000. GF Fund Management CO. LTD. bought a new stake in Vera Therapeutics during the 4th quarter worth approximately $56,000. KBC Group NV increased its holdings in Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after acquiring an additional 1,387 shares during the period. Finally, Summit Investment Advisors Inc. increased its holdings in Vera Therapeutics by 16.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after acquiring an additional 639 shares during the period. Institutional investors own 99.21% of the company's stock.
About Vera Therapeutics
(
Get Free Report)
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Further Reading
Before you consider Vera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.
While Vera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
